Vaxart Inc (VXRT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH141099D
- Pages: 31
- October 2018
- Total Views:1162
- Region : North America
- GlobalData
- Equity Research Report

Details
Summary
Vaxart Inc (Vaxart) is a clinical stage biotechnology company which develops oral recombinant protein vaccines based on its proprietary oral vaccine delivery platform to treat infections. The company develops tablet vaccines for seasonal and pandemic influenza, norovirus, and respiratory syncytial virus (RSV). Vaxart's vaccine delivery platform encompasses vector-adjuvant combination, which can be used with many recombinant antigens to develop vaccines for oral administration. The company's platform approach supports the rapid development of antigen based vaccines. It offers recombinant protein antigens such as marketed influenza, hepatitis B, human papilloma virus (HPV) vaccines, and other recombinant vaccines in industry pipeline. The company also conducts studies for the development of vaccine candidates for other indications. Vaxart is headquartered in South San Francisco, California, the US.
Vaxart Inc (VXRT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vaxart Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Vaxart Inc, Medical Devices Deals, 2012 to YTD 2018 9
Vaxart Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Vaxart Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Vaxart Raises USD 20 Million In Series C Financing Round 11
Vaxart Raises Additional USD 4.4 Million In Series B Financing 12
Partnerships 13
Vaxart Enters into Contract with BARDA 13
Merger 14
Aviragen Therapeutics Completes Merger With Vaxart 14
Debt Offering 15
Vaxart Raises USD18.4 Million in Private Placement of Notes 15
Vaxart Inc-Key Competitors 16
Vaxart Inc-Key Employees 17
Vaxart Inc-Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Financial Announcements 19
Aug 09, 2018: Vaxart announces second quarter 2018 financial results and corporate update 19
May 15, 2018: Vaxart Announces First Quarter 2018 Financial Results and Corporate Update 20
Corporate Communications 21
May 01, 2018: Vaxart Names Dr. David Taylor As Chief Medical Officer 21
Apr 19, 2018: Vaxart Appoints Brant Biehn As Senior Vice President, Commercial Operations 22
Clinical Trials 23
Jun 04, 2018: Vaxart Reports Topline Results from Phase 2 Trial of Teslexivir for the Treatment of Condyloma 23
Apr 02, 2018: Vaxart Announces Oral Presentation of Clinical Data from Oral Influenza Vaccine Program at the World Vaccine Congress 24
Jan 31, 2018: Vaxart Announces its Oral Flu Vaccine Significantly Reduced Rate of Influenza Infection in Phase 2 Challenge Study 25
Nov 29, 2017: Aviragen Therapeutics Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of Teslexivir (BTA074) for the Treatment of Condyloma 26
Oct 26, 2017: Vaxart Announces Positive Topline Results for its Oral Tablet Vaccine in Phase 2 Influenza Challenge Study 27
Feb 14, 2017: Vaxart Announces Positive Phase 1 Study of Oral Norovirus Vaccine 28
Feb 13, 2017: Aviragen Therapeutics Announces Top-Line Results from Phase 2b SPIRITUS Trial of Vapendavir 29
Feb 01, 2017: Aviragen Therapeutics Announces Top-Line Results from Phase 2a RSV Challenge Study of BTA585 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31
List Of Figure
List of Figures
Vaxart Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vaxart Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Vaxart Inc, Medical Devices Deals, 2012 to YTD 2018 9
List Of Table
List of Tables
Vaxart Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vaxart Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vaxart Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Vaxart Inc, Medical Devices Deals, 2012 to YTD 2018 9
Vaxart Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Vaxart Raises USD 20 Million In Series C Financing Round 11
Vaxart Raises Additional USD 4.4 Million In Series B Financing 12
Vaxart Enters into Contract with BARDA 13
Aviragen Therapeutics Completes Merger With Vaxart 14
Vaxart Raises USD18.4 Million in Private Placement of Notes 15
Vaxart Inc, Key Competitors 16
Vaxart Inc, Key Employees 17
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Vaxart Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Vaxart Inc (Vaxart) is a clinical stage biotechnology company which develops oral recombinant protein vaccines based on its proprietary oral vaccine delivery platform to treat infections. The company develops tablet vaccines for seasonal and pandemic influenza, norovirus, and respiratory syncytial virus (RSV). Vaxart's vaccine delivery platform encompasses vector-adjuvant combination, which can be used with many recombinant antigens to develop vaccines for oral administration. The company's platform approach supports the rapid development of antigen based vaccines. It offers recombinant protein antigens such as marketed influenza, hepatitis B, human papilloma virus (HPV) vaccines, and other recombinant vaccines in industry pipeline. The company also conducts studies for the development of vaccine candidates for other indications. Vaxart is headquartered in South San Francisco, California, the US.
Vaxart Inc (VXRT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vaxart Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Vaxart Inc, Medical Devices Deals, 2012 to YTD 2018 9
Vaxart Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Vaxart Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Vaxart Raises USD 20 Million In Series C Financing Round 11
Vaxart Raises Additional USD 4.4 Million In Series B Financing 12
Partnerships 13
Vaxart Enters into Contract with BARDA 13
Merger 14
Aviragen Therapeutics Completes Merger With Vaxart 14
Debt Offering 15
Vaxart Raises USD18.4 Million in Private Placement of Notes 15
Vaxart Inc-Key Competitors 16
Vaxart Inc-Key Employees 17
Vaxart Inc-Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Financial Announcements 19
Aug 09, 2018: Vaxart announces second quarter 2018 financial results and corporate update 19
May 15, 2018: Vaxart Announces First Quarter 2018 Financial Results and Corporate Update 20
Corporate Communications 21
May 01, 2018: Vaxart Names Dr. David Taylor As Chief Medical Officer 21
Apr 19, 2018: Vaxart Appoints Brant Biehn As Senior Vice President, Commercial Operations 22
Clinical Trials 23
Jun 04, 2018: Vaxart Reports Topline Results from Phase 2 Trial of Teslexivir for the Treatment of Condyloma 23
Apr 02, 2018: Vaxart Announces Oral Presentation of Clinical Data from Oral Influenza Vaccine Program at the World Vaccine Congress 24
Jan 31, 2018: Vaxart Announces its Oral Flu Vaccine Significantly Reduced Rate of Influenza Infection in Phase 2 Challenge Study 25
Nov 29, 2017: Aviragen Therapeutics Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of Teslexivir (BTA074) for the Treatment of Condyloma 26
Oct 26, 2017: Vaxart Announces Positive Topline Results for its Oral Tablet Vaccine in Phase 2 Influenza Challenge Study 27
Feb 14, 2017: Vaxart Announces Positive Phase 1 Study of Oral Norovirus Vaccine 28
Feb 13, 2017: Aviragen Therapeutics Announces Top-Line Results from Phase 2b SPIRITUS Trial of Vapendavir 29
Feb 01, 2017: Aviragen Therapeutics Announces Top-Line Results from Phase 2a RSV Challenge Study of BTA585 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31
List Of Figure
List of Figures
Vaxart Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vaxart Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Vaxart Inc, Medical Devices Deals, 2012 to YTD 2018 9
List Of Table
List of Tables
Vaxart Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vaxart Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vaxart Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Vaxart Inc, Medical Devices Deals, 2012 to YTD 2018 9
Vaxart Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Vaxart Raises USD 20 Million In Series C Financing Round 11
Vaxart Raises Additional USD 4.4 Million In Series B Financing 12
Vaxart Enters into Contract with BARDA 13
Aviragen Therapeutics Completes Merger With Vaxart 14
Vaxart Raises USD18.4 Million in Private Placement of Notes 15
Vaxart Inc, Key Competitors 16
Vaxart Inc, Key Employees 17
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Vaxart Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.